About Orthomimetics
Orthomimetics is a Healthcare company based in Cambridge (United Kingdom) founded in 2005, and was acquired by TiGenix in November 2009. Resorbable implant for minimally invasive repair of small osteochondral defects. Orthomimetics has raised $9.6 million across 1 funding round from investors including Schroders, TiGenix and Oxford Capital. The company has 2 employees. Its focus areas include Life Sciences, Regenerative Medicine, Biomaterials and Scaffolds. Its legal entity is ORTHOMIMETICS LIMITED.
Company details
Orthomimetics is a medical technology company founded as a spin-out from the University of Cambridge and the Massachusetts Institute of Technology (MIT). It combines three natural biomaterials collagen, glycosaminoglycans and calcium phosphate into bioresorbable tissue-regeneration scaffolds. The companys flagship product Chondromimetic is an off-the-shelf, resorbable implant for the minimally invasive repair of small osteochondral (cartilage and underlying bone) defects. The product has received European market approval (CE-Mark approval). Orthomimetics, is acquired by Belgium-based TiGenix for 23.8m.
- Headquarters Cambridge, United Kingdom
- Employees 2
- Stage Acquired
- SectorsHealthcare
- Website ww38.orthomimetics.com
- Acquired by TiGenix (Nov 2009)
- Legal Name Orthomimetics Limited
Funding Insights of Orthomimetics
Orthomimetics has successfully raised a total of $9.6M through 1 strategic funding round. The most recent funding activity was a Series A round of $9.6 million completed in December 2006. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $9.6M
- Total Rounds 1
- Last Round Series A — $9.6M
- First Round $9.6M
(Dec 2006)
- Investors Count 2
All 1 funding rounds of Orthomimetics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec 2006 | $9.6M | Series A | – | – |
3 investors in total: 3 institutional.
Investors in Orthomimetics
Orthomimetics has secured backing from 3 investors, including venture fund and institutional investors. Prominent investors backing the company include Schroders, TiGenix and Oxford Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Early-stage venture capital is invested in UK technology sectors. | oxcp.com | Oxford, United Kingdom | ||
Investment management and wealth management services are provided to clients. | 1804 | schroders.com | London, United Kingdom | |
Allogeneic stem cell-based therapies targeting autoimmune, inflammatory and heart diseases. | 2000 | tigenix.com | Leuven, Belgium |
Investor details for Orthomimetics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Orthomimetics
3 dated milestones of Orthomimetics across 4 years, from founding to its latest funding, stage changes and deals.
- Founded Orthomimetics is founded.
- Funding First funding round of $9.6M.
- Exit Acquired by TiGenix.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Orthomimetics
Orthomimetics was founded in 2005 and raised its 1st funding round 1 year after it was founded.
Orthomimetics is headquartered in Cambridge, United Kingdom. It is registered at Cambridge, Cambridgeshire, United Kingdom.
Orthomimetics is a funded company, having raised a total of $9.6M across 1 funding round to date. The company's 1st funding round was a Series A of $9.6M, raised on Dec 2006.
Orthomimetics has 2 employees.
Orthomimetics is a medical technology company founded as a spin-out from the University of Cambridge and the Massachusetts Institute of Technology (MIT). It combines three natural biomaterials collagen, glycosaminoglycans and calcium phosphate into bioresorbable tissue-regeneration scaffolds. The companys flagship product Chondromimetic is an off-the-shelf, resorbable implant for the minimally invasive repair of small osteochondral (cartilage and underlying bone) defects. The product has received European market approval (CE-Mark approval). Orthomimetics, is acquired by Belgium-based TiGenix for 23.8m.
Orthomimetics has 3 investors. Key investors include Schroders, TiGenix, and Oxford Capital.
Orthomimetics operates through Orthomimetics Limited.
Yes. Orthomimetics was acquired by TiGenix in November 2009.